CG’s newest late-stage bladder cancer results broaden potential
CG Oncology’s phase 3 results show that its immunotherapy can have a wider impact on certain patients with non-muscle invasive bladder cancer.
CG Oncology is a late-stage clinical biopharmaceutical company developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy, for non-muscle invasive bladder cancer. Its Phase 3 program spans BOND-003 in BCG-unresponsive disease and PIVOT-006 as adjuvant monotherapy in intermediate-risk disease following TURBT, with earlier studies exploring high-risk and BCG-naïve populations.
CG Oncology’s phase 3 results show that its immunotherapy can have a wider impact on certain patients with non-muscle invasive bladder cancer.
Chief Executive Officer